Informed Investing

OCTOBER 13, 2026

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The Motley Fool

Johnson & Johnson and Pfizer present distinct investment opportunities in the healthcare sector for 2026. J&J boasts robust sales from its Innovative Medicine and MedTech segments, with a projected revenue of up to $101.4 billion and a strong dividend history. In contrast, Pfizer focuses on biopharmaceuticals, facing challenges...

Four Kinds of Dividend Stocks That Rising Rates Don't Hurt

In a climate of rising bond yields, many high dividend stocks have suffered, with Realty Income and NextEra dropping significantly. However, companies like Chevron and ADP have thrived, showcasing four types of resilient dividend stocks. For high-income professionals seeking stability in their portfolios, this video highlights...

#Market Trends

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The Motley Fool

Four Kinds of Dividend Stocks That Rising Rates Don't Hurt